ACE2 and COVID-19: Though mitochondrial swelling, endoplasmic reticulum dilatation, glycogen granule depletion in hepatocytes [41], and raised alanine and aspartate aminotransferases have been found in COVID-19 patients in many studies, suggesting [42,43] that liver infection contributes to hepatic impairment in COVID-19 patients, there was no robust data on presence of SARS-CoV-2 in solid organs, e.g., liver and pancreas, despite the presence of ACE-2 in these organs.